Latanoprost Stada (Latanoprost)

Latanoprost is a prostaglandin F2α analogue that activates FP receptors in the eye, leading to remodeling of the extracellular matrix in the ciliary body. This enhances uveoscleral outflow of aqueous humor, thereby decreasing intra‑ocular pressure.

The dosing regimen for Latanoprost Stada is determined by the prescribing clinician. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact dose and schedule should follow the prescriber’s instructions.

Safety data for Latanoprost in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Latanoprost belongs to the prostaglandin analogue class, which generally provides greater IOP reduction with once‑daily dosing compared with beta‑blockers or carbonic anhydrase inhibitors. Its side‑effect profile is distinct, often causing cosmetic changes such as increased eyelash length and iris darkening.

Latanoprost Stada should be stored at room temperature, below 25 °C, in its original packaging. Protect the bottle from light and moisture to maintain stability and potency.

Latanoprost is administered as an ophthalmic solution. The patient places one drop into the prescribed eye(s) once daily, preferably in the evening, avoiding contact with the tip of the bottle to maintain sterility.

Serious risks, though rare, include uveitis, macular edema, and severe allergic reactions that may cause swelling, itching, or rash around the eye. Any sudden vision changes or severe eye pain should prompt immediate medical evaluation.

Latanoprost is contraindicated in patients with active ocular inflammation, such., uveitis, or ocular infection. Individuals with known hypersensitivity to latanoprost or any component of the formulation should also avoid its use.